90%Confidence
0Views
FDASource
2026-03-29Date
Summary
New Life Pharma's Class II FDA recall for Semaglutide injection due to sterility assurance issues poses significant patient safety risks for this popular diabetes/weight-loss drug. This could trigger regulatory penalties, erode trust in compounding pharmacies, and potentially affect market access for compounded semaglutide products.
Actionable: Evaluate exposure to New Life Pharma and similar compounding pharmacies, and consider diversifying semaglutide sourcing to mitigate supply chain risks.
AI Confidence: 90%
Data Points
firmNew Life Pharma LLC
classificationClass II
statusOngoing
distributionOH
productSemaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-06
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now